{{Rsnum
|rsid=17015014
|Chromosome=4
|position=141807619
|Orientation=plus
|GMAF=0.2686
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 1.8 | 33.6 | 64.6
| HCB | 24.1 | 43.8 | 32.1
| JPT | 16.8 | 54.9 | 28.3
| YRI | 0.0 | 11.6 | 88.4
| ASW | 1.8 | 33.3 | 64.9
| CHB | 24.1 | 43.8 | 32.1
| CHD | 22.9 | 52.3 | 24.8
| GIH | 3.0 | 35.6 | 61.4
| LWK | 0.0 | 6.4 | 93.6
| MEX | 25.9 | 51.7 | 22.4
| MKK | 0.0 | 12.8 | 87.2
| TSI | 2.0 | 15.7 | 82.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17015014
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.19, combined P value= 1.11E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470186
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17015014
|overall_frequency_n=28
|overall_frequency_d=128
|overall_frequency=0.21875
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}